Cost-effectiveness analysis based on the number-needed-to-treat: Common sense or non-sense?

Health Economics

Volumn 13, Issue 1, 2004, Pages 9-19

  Kristiansen, Ivar Sønbø ^a   Gyrd Hansen, Dorte ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Cost effectiveness analysis; Economic evaluation; Number needed to treat; Survival analysis

Indexed keywords

ACCURACY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION MAKING; DENTAL CARIES; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH ECONOMICS; HEART INFARCTION; HIP FRACTURE; HUMAN; INTRAUTERINE INFECTION; METHODOLOGY; MULTIPLE SCLEROSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROBABILITY; PUBLICATION; REVIEW; RISK REDUCTION; SURVIVAL; VIRUS INFECTION;

COST-BENEFIT ANALYSIS; HUMANS; MODELS, STATISTICAL; SURVIVAL ANALYSIS;

EID: 0347093498     PISSN: 10579230     EISSN: None     Source Type: Journal    
DOI: 10.1002/hec.797     Document Type: Review

References (32)

1. Sackett DL, Richardson WS, Rosenberg W, Haynes RB. Evidence-Based Medicine. How to Practice and Teach EBM. Churchill Livingstone: New York, 2000.
2. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Eng J Med 1988; 318: 1728-1733.
3. Hutton JL. Number needed to treat: properties and problems. J R Statist Soc 2000; 163: 403-419.
4. Sackett DL. On some clinically useful measures of the effect of treatment. Evidence Based Med 1996; 1: 37-38.
5. Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analyses - sometimes informative, usually misleading. BMJ 1999; 318: 1548-51.
6. Torp-Pedersen C, Kober L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet 1999; 354: 9-12.
7. Kristiansen IS, Gyrd-Hansen D, Nexoe J, Nielsen JB. Number needed to treat: Easily understood and intuitively meaningful? Theoretical considerations and a randomised trial. J Clin Epidemiol 2002; 55: 888-892.
8. Nexoe J, Gyrd-Hansen D, Kragstrup J, Kristiansen IS, Nielsen JB. Danish GPs' perception of disease risk and benefit of intervention. Fam Pract 2002; 19: 3-6.
9. San Laureano JA, Briganti EM, Colville DJ. Number needed to treat: a useful new method of assessing the magnitude of treatment effect and its application to the management of diabetic retinopathy. Aus NZJ Ophthalmo 1999; 27: 137-142.
10. McAlister FA, Straus SE, Guyatt GH, Haynes RB. Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. Evidence-Based Medicine Working Group. JAMA 2000; 283: 2829-2836.
11. Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Eng J Med 1990; 323: 1289-1298.
12. Hochberg MC, Ross PD, Black D et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 1999; 42: 1246-1254.
13. Riegelman R, Schroth WS. Adjusting the number needed to treat: incorporating adjustments for the utility and timing of benefits and harms. Med Decis Making 1993; 13: 247-252.
14. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 1997; 16: 33-64.
15. Torgerson DJ, Kanis JA. Cost-effectiveness of preventing hip fractures in the elderly population using vitamin D and calcium. QJM 1995; 88: 135-139.
16. Connor N, Roberts J, Nicoll A. Strategic options for antenatal screening for syphilis in the United Kingdom: a cost effectiveness analysis. J Med Screen 2000; 7: 7-13.
17. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999; 104: 419-427.
18. Robbins JM, Tilford JM, Jacobs RF, Wheeler JG, Gillaspy SR, Schutze GE. A number-needed-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalization. Arch Pediatr Adolesc Med 1998; 152: 358-366.
19. Ola B, Papaioannou S, Afnan MA, Hammadieh N, Gimba S. Recombinant or urinary follicle-stimulating hormone? A cost-effectiveness analysis derived by particularizing the number needed to treat from a published meta-analysis. Fertil Steril 2001; 75: 1106-1110.
20. Saint S, Veenstra DL, Sullivan SD, Chenoweth C, Fendrick AM. The potential clinical and economic benefits of silver alloy urinary catheters in preventing urinary tract infection. Arch Intern Med 2000; 160: 2670-2675.
21. Kopjar B, Wickizer TM. Age gradient in the cost-effectiveness of bicycle helmets. Prev Med 2000; 30: 401-406.
22. Feuer DJ, Broadley KE. Systematic review and meta-analysis of corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancers. Systematic Review Steering Committee. Ann Oncol 1999; 10: 1035-1041.
23. van Rijkom HM, Truin GJ, Hof MA. A meta-analysis of clinical studies on the caries-inhibiting effect of fluoride gel treatment. Caries Res 1998; 32: 83-92.
24. Caro J, Klittich W, McGuire A et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ 1997; 315: 1577-1582.
25. Franzosi MG, Brunetti M, Marchioli R, Marfisi RM, Tognoni G, Valagussa F. Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial. Pharmacoeconomics 2001; 19: 411-420.
26. Forbes RB, Lees A, Waugh N, Swingler RJ. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis. BMJ 1999; 319: 1529-1533.
27. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 1998; 352: 1491-1497.
28. Skribeland NO. Pharmacoeconomic evaluation of Fosamax. Costly prevention of hip fracture. Nytt om legemidler 1997; 6: 123-128 (in Norwegian).
29. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-1541.
30. Kopjar B, Bjorndal A. Prevention of osteoporosis-related fractures with alendronate. Tidsskr Nor Laegeforen 1998; 118: 518-519 (in Norwegian).
31. Sinclair JC, Cook RJ, Guyatt GH, Pauker SG, Cook DJ. When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment. J Clin Epidemiol 2001; 54: 253-262.
32. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996; 313: 275-283.